A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, ...

CRISPR Therapeutics AG recently reported its fourth-quarter and full-year 2025 results, showing revenue falling to US$0.864 million in Q4 and US$3.51 million for the year, alongside wider net losses ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Scientists in China report removing HIV from human DNA using gene-editing technology. Experts say the findings are promising but still far from a confirmed cure.

Researchers developed a CRISPR-based system that spreads through bacterial populations to disable antibiotic resistance genes ...

Biotech futurist Juan Enriquez explores how gene editing tools like CRISPR could reshape humanity within a century. The ...

Researchers used CRISPR gene editing to selectively kill cancer cells with amplified oncogenes. In animal and cellular models ...

A novel CRISPR-based technology can spread within bacterial populations to eliminate antibiotic resistance.

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

A sales partner offered a ray of hope that this company couldn't for itself.

A new CRISPR-powered light sensor can detect the faintest whispers of cancer in a single drop of blood.

Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.